MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) — Eikon Therapeutics, Inc. (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to address serious unmet medical needs, today announced the pricing of its upsized initial public offering of 21,177,600 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Eikon has granted the underwriters a 30-day option to purchase up to an additional 3,176,640 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The gross proceeds to Eikon from the offering, without giving effect to the underwriters’ option to purchase additional shares and before deducting underwriting discounts and commissions and offering expenses payable by Eikon, are expected to be approximately $381 million.
Source: Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering